Does fluciclovine PET improve the ability to differentiate brain met recurrence from necrosis following SRS?
Does radium-223 improve survival when added to enzalutamide for patients with mCRPC?
Were there any grade 3+ adverse events in the SHIFT trial when an ultrahypofractionted boost was given after ultrahypofractionated whole breast RT?
Did a meta-analysis show a survival benefit from adding ADT to postoperative radiation for prostate cancer when the PSA is low (<0.5)?
Answers
Possibly. This study established visual criteria for differentiating the two with a specificity of >90%.
Yes. In PEACE-3, adding radium-223 significantly improved OS and radiographic PFS in those with mCRPC without visceral metastases.
No. Dermatitis, the most frequent adverse event, peaked during week 2 (35% grade 1, 0.5% grade 2). Any grade breast pain was seen in 32.3%, and any grade edema was seen in 27.2%.
No. This massive meta-analysis suggests there is little survival benefit from adding ADT to early PORT for prostate cancer when the PSA is 0.5 or less. Even with a PSA above 0.5, the absolute benefit of ADT (and particularly long term ADT) is mainly seen in those with significantly elevated PSA of 1.6 or more. | QuadShot News
Does radium-223 improve survival when added to enzalutamide for patients with mCRPC?
Were there any grade 3+ adverse events in the SHIFT trial when an ultrahypofractionted boost was given after ultrahypofractionated whole breast RT?
Did a meta-analysis show a survival benefit from adding ADT to postoperative radiation for prostate cancer when the PSA is low (<0.5)?
Answers
Possibly. This study established visual criteria for differentiating the two with a specificity of >90%.
Yes. In PEACE-3, adding radium-223 significantly improved OS and radiographic PFS in those with mCRPC without visceral metastases.
No. Dermatitis, the most frequent adverse event, peaked during week 2 (35% grade 1, 0.5% grade 2). Any grade breast pain was seen in 32.3%, and any grade edema was seen in 27.2%.
No. This massive meta-analysis suggests there is little survival benefit from adding ADT to early PORT for prostate cancer when the PSA is 0.5 or less. Even with a PSA above 0.5, the absolute benefit of ADT (and particularly long term ADT) is mainly seen in those with significantly elevated PSA of 1.6 or more. | QuadShot News